.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent clinical trial results highlight a significant advancement in the management of advanced soft tissue sarcoma (STS). Researchers investigated the efficacy of combining standard-of-care doxorubicin with durvalumab, a PD-L1 immune checkpoint inhibitor. This doxorubicin and durvalumab sarcoma study focused on anthracycline-naïve patients with metastatic or recurrent disease. Consequently, the findings provide a potential new pathway for improving patient outcomes in a challenging oncological setting.
The Phase II portion of the trial evaluated 41 patients to determine the objective response rate (ORR). Specifically, the combination therapy achieved an ORR of 31.7%, with one patient reaching a complete response and twelve others showing partial responses. Furthermore, the median progression-free survival (PFS) reached 7.6 months. The median overall survival was also impressive at 23.8 months. These results suggest that adding immunotherapy to traditional chemotherapy might enhance the durability of the treatment response.
Safety is a paramount concern when combining cytotoxic drugs with immunotherapy. In this study, the phase IB portion established a recommended dose of 75 mg/m2 for doxorubicin. Common grade 3-4 adverse events included neutropenia, thrombocytopenia, and anemia. However, researchers noted that the toxicity profile remained acceptable and manageable within standard clinical protocols. Moreover, correlative analyses identified high PD-1 expression and the absence of RTK-RAS pathway alterations as key predictors for better survival.
The trial reported a median progression-free survival of 7.6 months and a median overall survival of 23.8 months for patients treated with the combination.
The absence of genetic alterations in the RTK-RAS pathway and high levels of PD-1 expression were identified as independent predictors for longer progression-free survival.
The most frequent grade 3-4 adverse events reported were hematological, specifically neutropenia, thrombocytopenia, and anemia.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.
References
Yun KH et al. Phase IB/II Trial with Correlative Analyses of Doxorubicin plus Durvalumab Combination in Patients with Advanced Soft Tissue Sarcoma. Clin Cancer Res. 2026 Feb 06. doi: 10.1158/1078-0432.CCR-25-2633. PMID: 41649866.
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 1.2025.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A Phase IB/II trial demonstrates that doxorubicin plus durvalumab offers a 31.7% ORR and manageable safety profile in patients with advanced soft tissue sar...
5 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
